Decreased levels of myeloid progenitor cells associated with long-term administration of recombinant human granulocyte colony-stimulating factor in patients with autoimmune neutropenia

Br J Haematol. 1993 Mar;83(3):384-7. doi: 10.1111/j.1365-2141.1993.tb04660.x.

Abstract

We studied the long-term in vivo effect of recombinant human granulocyte colony stimulating factor (rhG-CSF) on in vitro growth of granulocyte/macrophage colony forming cells (GM-CFC) in bone marrow and peripheral blood obtained from two patients with autoimmune neutropenia, who received rhG-CSF. Along with rhG-CSF treatment for more than 40 d, numbers of GM-CFC-derived colonies from both bone marrow and peripheral blood gradually decreased to a significant level though white blood cells in peripheral blood and nucleated cells in bone marrow were increased in number. This observation suggests that long-term administration of rhG-CSF may preferentially activate a differentiation pathway for granulopoiesis while proliferation of GM-CFC is not induced as expected in response to rhG-CSF.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Autoimmune Diseases / pathology*
  • Blood Cell Count
  • Bone Marrow / pathology*
  • Colony-Forming Units Assay
  • Female
  • Granulocyte Colony-Stimulating Factor / therapeutic use*
  • Granulocytes / pathology
  • Hematopoietic Stem Cells / pathology*
  • Humans
  • Macrophages / pathology
  • Male
  • Middle Aged
  • Neutropenia / blood
  • Neutropenia / pathology*
  • Neutropenia / therapy
  • Recombinant Proteins / therapeutic use
  • Time Factors

Substances

  • Recombinant Proteins
  • Granulocyte Colony-Stimulating Factor